雷珠单抗治疗渗出性年龄相关性黄斑变性患者的心血管风险:全国自身对照病例系列研究
自身对照病例系列分析显示,总体暴露期卒中风险未升高,但暴露≥57天时段卒中风险轻度升高,急性心肌梗死与雷珠单抗无关联。
要点
- 雷珠单抗总体暴露期卒中风险未增加(IRR=0.83,95%CI 0.75-0.91)。
- 暴露≥57天时段卒中风险轻度升高(IRR=1.14,95%CI 1.001-1.31)。
- 未发现雷珠单抗与急性心肌梗死存在关联。
核心结论
- 玻璃体腔注射雷珠单抗未增加卒中或急性心肌梗死的总体风险。
- 高危患者连续每月使用雷珠单抗时的心血管风险应审慎评估。
研究设计与样本
- 基于韩国国民健康保险数据库的全国自身对照病例系列研究(self-controlled case series)。
- 采用条件Poisson回归比较雷珠单抗暴露期与基线的发病率比(IRR)。
主要发现
- 总体暴露期卒中风险未升高(IRR=0.83,95%CI 0.75-0.91)。
- 暴露≥57天时段卒中风险轻度升高(IRR=1.14,95%CI 1.001-1.31)。
- 暴露期出血性卒中(IRR=1.01,95%CI 0.80-1.26)与缺血性卒中(IRR=0.78,95%CI 0.71-0.86)风险均未升高。
- 暴露≥57天时段缺血性与出血性卒中风险轻度升高。
- 未发现雷珠单抗与急性心肌梗死存在关联。
关键数值与推荐
- 卒中总体暴露期IRR=0.83(95%CI 0.75-0.91)。
- 暴露≥57天时段卒中IRR=1.14(95%CI 1.001-1.31)。
- 出血性卒中暴露期IRR=1.01(95%CI 0.80-1.26)。
- 缺血性卒中暴露期IRR=0.78(95%CI 0.71-0.86)。
临床怎么用
- 提示雷珠单抗玻璃体腔注射总体心血管风险较低。
- 对心血管高危患者长期连续每月使用雷珠单抗需个体化权衡。
- 关注暴露时间较长(≥57天)患者的卒中风险信号。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To identify the association between ranibizumab and risk of stroke and acute myocardial infarction (AMI) in patients with exudative age-related macular degeneration (AMD). METHODS: We identified patients aged ≥45 years who received ranibizumab for exudative AMD from the Korean National Health Insurance database. Of these, we selected patients suffering stroke or AMI for the self-controlled case series. We estimated incidence rate ratios (IRR) for stroke or AMI by comparing incidence rates of ranibizumab-exposed periods to that of baseline using conditional Poisson regression. The risks of haemorrhagic and ischaemic strokes were also calculated separately. RESULTS: Among 33 134 patients receiving ranibizumab, 2397 patients had stroke or AMI. The risk of stroke (IRR=0.83, 95% CI 0.75 to 0.91) was not increased during the overall exposed period; however, there was a marginally elevated risk in ≥57 days exposed period (IRR=1.14, 95% CI 1.001 to 1.31). When analysing by the types of stroke, no increased risks of haemorrhagic (IRR=1.01, 95% CI 0.80 to 1.26) and ischaemic stroke (IRR=0.78, 95% CI 0.71 to 0.86) were observed during the exposed period, although the risks of ischaemic and haemorrhagic stroke were slightly elevated during ≥57 days exposed period. We could not find an association between ranibizumab and AMI. CONCLUSIONS: Ranibizumab intravitreal injections did not increase the overall risk of stroke or AMI. Although the cardiovascular risk in patient receiving ranibizumab seems to be low, continuous monthly use of ranibizumab for high-risk patients should be judged carefully.
引用
- Jeon HL, Byun SJ, Pratt NL, et al. Cardiovascular risk in patients receiving ranibizumab for exudative age-related macular degeneration: a nationwide self-controlled case-series study. Br J Ophthalmol. 2020. PMID: 32522792. doi:10.1136/bjophthalmol-2020-316373
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。